Enlivex Therapeutics (NASDAQ:ENLV) Issues Earnings Results

Enlivex Therapeutics (NASDAQ:ENLV) released its quarterly earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.07), Zacks reports.

Enlivex Therapeutics Stock Performance

ENLV traded down $0.01 during midday trading on Wednesday, hitting $0.95. The stock had a trading volume of 24,113 shares, compared to its average volume of 154,239. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.59. The business has a fifty day moving average of $1.09 and a 200 day moving average of $1.23. The company has a market cap of $20.23 million, a P/E ratio of -0.96 and a beta of 1.11.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Enlivex Therapeutics in a research note on Monday, March 3rd. HC Wainwright upped their target price on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, March 24th.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.